Hardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal

Hardman & Co Research 
Hardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal 
 
08-Aug-2019 / 10:45 GMT/BST 
 
*Hardman & Co: Nearing the end-goal* 
 
AVO's goal is to deliver an affordable and novel proton beam therapy (PBT) 
system, based on state-of-the-art technology developed originally at the 
world-renowned CERN. 2018 was characterised by the achievement of a number of 
technical milestones, including successful integration and validation of all 
the module types that constitute the LIGHT accelerator, thereby de-risking the 
project. AVO is delivering on its schedule to have the first LIGHT machine set 
up in Daresbury (Cheshire) ready for treating first patients by the end of 
2020, while completing the final building stage at the Harley Street site. 
 
Please click here for the full report: 
 
https://www.hardmanandco.com/research/corporate-research/nearing-the-end-goal/ 
[1] 
 
If you are interested in meeting the company, you can register your interest 
by clicking on the above link. 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the world with high-quality research, investor engagement programmes 
and advisory services. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
854449 08-Aug-2019 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f041e309c61419071ced4179a6fbc797&application_id=854449&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=854449&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

August 08, 2019 05:45 ET (09:45 GMT)